Brainstorm Cell Therapeut... (BCLI)
Brainstorm Cell Therapeutics Statistics
Share Statistics
Brainstorm Cell Therapeutics has 6.52M shares outstanding. The number of shares has increased by 21.47% in one year.
| Shares Outstanding | 6.52M |
| Shares Change (YoY) | 21.47% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 4.81% |
| Shares Floating | 5.07M |
| Failed to Deliver (FTD) Shares | 2.17K |
| FTD / Avg. Volume | 1.52% |
Short Selling Information
The latest short interest is 107.23K, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 107.23K |
| Short % of Shares Out | 1.64% |
| Short % of Float | 2.12% |
| Short Ratio (days to cover) | 2.86 |
Valuation Ratios
The PE ratio is 1.04 and the forward PE ratio is -0.67. Brainstorm Cell Therapeutics's PEG ratio is 0.
| PE Ratio | 1.04 |
| Forward PE | -0.67 |
| PS Ratio | 14.2 |
| Forward PS | 0.3 |
| PB Ratio | -1.55 |
| P/FCF Ratio | -1.33 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Brainstorm Cell Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04, with a Debt / Equity ratio of -0.09.
| Current Ratio | 0.04 |
| Quick Ratio | 0.04 |
| Debt / Equity | -0.09 |
| Debt / EBITDA | - |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $31.44K |
| Profits Per Employee | $430.48K |
| Employee Count | 27 |
| Asset Turnover | 0.46 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -90.39% in the last 52 weeks. The beta is 0.59, so Brainstorm Cell Therapeutics's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | -90.39% |
| 50-Day Moving Average | 1.5 |
| 200-Day Moving Average | 2.74 |
| Relative Strength Index (RSI) | 19.61 |
| Average Volume (20 Days) | 143.09K |
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of 849K and earned 11.62M in profits. Earnings per share was 2.19.
| Revenue | 849K |
| Gross Profit | 849K |
| Operating Income | 0 |
| Net Income | 11.62M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | 2.19 |
Balance Sheet
The company has 187K in cash and 720K in debt, giving a net cash position of -533K.
| Cash & Cash Equivalents | 187K |
| Total Debt | 720K |
| Net Cash | -533K |
| Retained Earnings | -226.64M |
| Total Assets | 1.83M |
| Working Capital | -8.59M |
Cash Flow
In the last 12 months, operating cash flow was -9.09M and capital expenditures 0, giving a free cash flow of -9.09M.
| Operating Cash Flow | -9.09M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.09M |
| FCF Per Share | -1.71 |
Margins
Gross margin is 100%, with operating and profit margins of 0% and 1369.02%.
| Gross Margin | 100% |
| Operating Margin | n/a |
| Pretax Margin | 1369.02% |
| Profit Margin | 1369.02% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1071.02% |
Dividends & Yields
BCLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BCLI is $30, which is 3847.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 3847.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 1, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 1, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -199.57 |
| Piotroski F-Score | 1 |